Hydralazine - Therapeutic use
Research News and Information

Monday, November 23, 2009

Heart failure in women: a need for prospective data.

2 Aug 2009 Heart failure affects 5 million Americans, and nearly 50% of these are women. Sex differences have been noted regarding the underlying etiology, pathophysiology, and prognosis. Women are less likely to have coronary artery disease and more likely ... Read more...

Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.

18 Jul 2009 Hypertension-induced diastolic heart failure accounts for a large proportion of all heart failure presentations. Hypertension also induces left ventricular (LV) hypertrophy. Fixed-dose isosorbide dinitrate/hydralazine (HISDN) decreased mortality in ... Read more...

The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs).

14 Jul 2009 BACKGROUND: We have tested the effects of aminopeptidase A (APA), MgSO(4) and various conventional antihypertensive drugs on hypertension in pregnant spontaneously hypertensive rats (SHRs) and examined the effects on both fetal heart and kidney. ... Read more...

Latest indexed articles for 'Hydralazine - Therapeutic use'

These are the very latest articles for this heading:

• Heart failure in women: a need for prospective data. 2 Aug 2009
• Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. 18 Jul 2009
• The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs). 14 Jul 2009
• Hydralazine-induced cholestatic hepatitis. 29 Jun 2009
• Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. 27 Feb 2009
• Have we witnessed the rise and fall of race-specific drugs? 27 Feb 2009
• Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. 24 Feb 2009
• Pharmacotherapeutic options for the treatment of preeclampsia. 13 Feb 2009
• Bioactivation of organic nitrates and the mechanism of nitrate tolerance. 30 Dec 2008
• Race-based medicine and justice as recognition: exploring the phenomenon of BiDil. 30 Dec 2008
• From the editors. 30 Dec 2008
• Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. 21 Dec 2008
• Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. 30 Nov 2008
• Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. 29 Nov 2008
• "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. 29 Nov 2008
• [Recent findings on nitrates: their action, bioactivation and development of tolerance] 20 Oct 2008
• Pharmacogenetics, race and global injustice. 30 Jul 2008
• Pseudomelanosis duodeni in a child with chronic renal failure. 29 Jun 2008
• Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers. 29 Jun 2008
• Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. 24 May 2008

See a longer list of these articles.

Technical information about 'Hydralazine'

Definition: A direct-acting vasodilator that is used as an antihypertensive agent.

Chemical name: 1(2H)-Phthalazinone, hydrazone

Registry Number: 86-54-4

Descriptor UI: D006830

Alternative terms: Hydralazine; Hydrallazin; Hydrazinophthalazine; Apressin; Nepresol; Hydralazine mono-Hydrochloride; Hydralazine mono Hydrochloride; mono-Hydrochloride, Hydralazine; Apressoline; Apresoline; Hydralazine Hydrochloride; Hydrochloride, Hydralazine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antihypertensive Agents; Vasodilator Agents;

Tree Number: D03.383.710.605.500;